In the following, therapies designed to modulate tau pathology and microglial activity will be explored in greater detail, highlighting their potential to complement oxidative stress-targeting strategies and contribute to a multifaceted approach to AD treatment. This evidence concerns the gene MAPT and Alzheimer disease.